BioStock: Positive subgroup data in SynAct Pharmas’s EXPAND study
Biotech SynAct Pharma has unveiled additional data from its EXPAND phase II clinical trial with resomelagon for rheumatoid arthritis. The new findings indicate consistent responsiveness to the drug candidate in a sub-population of patients with c-reactive protein level exceeding 3 mg/L, which is an indicative for active systemic inflammation. These encouraging findings are important for further development of resomelagon, according to the company’s CSO Thomas Jonassen in an interview.
SynAct Pharma announces additional data from the EXPAND P2b clinical trial and identifies population with responsiveness to resomelagon
Webcasted telephone conference: Wednesday September 13th at 15:00 p.m. CEST.
SynAct Pharma announces top line data from the 12-week EXPAND P2b clinical trial in severely active newly diagnosed rheumatoid arthritis patients
September 4, 2023
A webcasted telephone conference will be held September 4th at 15:00 CEST.
SynAct Pharma completes dosing in part A of combined Phase 2a/b RESOLVE study of resomelagon (AP1189) in rheumatoid arthritis (RA)
Interim Report Q2 2023
SynAct Pharma AB (publ) published its Q2 report for 2023 on August 4 at 07.30 CEST.
Webcast and telephone conference: at 15:00 CEST the same day.
Torbjørn Bjerke comments on the additional data from the Expand clinical trial – September 13, 2023
CEO Torbjørn Bjerke at Börsveckan’s Seminar (Swedish) – September 6, 2023
Resolving Inflammation Without Immunosuppression
Most available treatments used to treat inflammation suppress the immune system which can lead to a heightened risk of serious safety issues. Inflammation resolution strategies seek to provide both anti-inflammatory and pro-resolving activity without suppressing the immune system.
Harnessing the Melanocortin System to Resolve Inflammation
SynAct harnesses the melanocortin system to stimulate both anti-inflammatory and inflammation resolution mechanisms to resolve excessive inflammation safely without suppressing the immune system’s ability to respond to new infections or injuries.
Resomelagon (AP1189)
An Oral Selective Melanocortin Agonist
Our lead drug candidate resomelagon (AP1189) is a once-daily oral selective melanocortin agonist that selectively stimulates melanocortin receptors to help the body resolve inflammation. Resomelagon (AP1189) is being evaluated in rheumatoid arthritis (RA), idiopathic membranous nephropathy (iMN) and respiratory insufficiency caused by viruses like COVID-19.
-
September 12, 2023 RegulatorySynAct Pharma announces additional data from the EXPAND P2b clinical trial and identifies population with responsiveness to resomelagon
-
September 4, 2023 RegulatorySynAct Pharma announces top line data from the 12-week EXPAND P2b clinical trial in severely active newly diagnosed rheumatoid arthritis patients
-
August 4, 2023 RegulatorySynAct Pharma publishes Q2 2023 interim report
-
May 5, 2023 RegulatorySynAct Pharma publishes Q1 2023 interim report
-
September 19, 2023BioStock: Positive subgroup data in SynAct Pharmas’s EXPAND study
-
September 13, 2023EXPAND study update
A MESSAGE FROM OUR CEO
“We are truly at an exciting inflection point for SynAct. I am excited to continue to work with the talented management team we have at SynAct, and we are all eagerly awaiting the upcoming clinical trial results that will build off the strong data demonstrated in the BEGIN study. I want to express our sincere appreciation to our shareholder base for supporting our shared vision of resomelagon and the promise of resolution therapy. Our combined resolve remains strong.”